Navigation Links
Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference

l Cancer Trial

To date, eight patients have been dosed in this trial, of which seven have stabilized disease. Two of the seven patients have tumor shrinkage, one of 40% (partial response according to RECIST) and one of 15%. The patients have experienced no increase in drug-related toxicity. The Simon two-stage designed study is an open-label, multi-center trial of DAVANAT(R) in combination with 5-FU in a regimen with Avastin(R) and leucovorin in up to 50 patients with locally advanced, unresectable or metastatic colorectal cancer and who are unable to tolerate intensive chemotherapy. The primary objectives of the trial are tumor shrinkage and progression-free survival. Six sites are actively recruiting patients. Additional sites are expected to be active shortly.

Phase II, First Line, Biliary Cancer Trial

To date, five patients have been dosed in this trial, of which four have stabilized disease. One patient has 35% tumor shrinkage. The patients have experienced no increase in drug-related toxicity. A cholangiocarcinoma (bile duct cancer) patient from the Phase I trial remained on study for 13 months, far exceeding expectations. The Simon two-stage designed study is an open-label, multi-center trial to evaluate the efficacy and safety of DAVANAT(R) in combination with 5-FU in up to 42 patients. The primary objectives are complete/partial tumor response (RECIST) and progression-free survival. Three sites are actively recruiting patients. Three additional sites are expected to be active shortly.

Additional information on these two trials and participating sites can be found at www.clinicaltrials.gov website, key word: DAVANAT(R).

About DAVANAT(R)

DAVANAT(R), the Company's lead drug candidate, is a polysaccharide (carbohydrate polymer) composed of mannose and galactose (galactomannan). The Company believes DAVANAT(R)'s mechanism of action is based upon binding to lectins on the cell surface. It is theorized that DAVANAT(R) targ
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:7/27/2015)... 2015   DocResponse was ranked the ... a peer-reviewed study , "Evaluation of symptom ... published in the July issue of The British ... Medical School researchers determined that performance of online ... correct diagnosis first in standardized patient evaluations more ...
(Date:7/27/2015)... NAMUR , Belgium , July ... MKT: VNRX), a life sciences company focused on developing ... types and other conditions, today announced that it has ... research organization, Global Specimen Solutions, Inc. (GSS), to support ... colorectal cancer tests. Under the agreement, ...
(Date:7/27/2015)... , July 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... Asia-Pacific, ROW) - Global Forecast to 2019" report ... expected to reach a value of $2.1 Billion by ... of 3.5% during the forecast period. ...
Breaking Medicine Technology:Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
...  Integware today announced that it has signed a ... PLM Software, a leading global provider of product ... focused for nearly twenty years on extending PLM ... industry. Its platform-neutral development approach enables it to ...
... FLORHAM PARK, N.J., Jan. 25, 2012  Shionogi Inc., the ... announced results from two studies published online today in ... the first study, a randomized, double-blind, placebo-controlled phase III ... 3-16 with problem drooling due to neurologic conditions demonstrated ...
Cached Medicine Technology:Integware Announces Systems Integrator Agreement With Siemens PLM Software 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8
(Date:7/28/2015)... ... July 28, 2015 , ... ... the 2015 NCW Eco-Excellence Award for the Nutrition Beverage category. Established by NCW ... and elevate companies that stand out for their social and environmental sustainability. , ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... has been named the regional winner of the EY Entrepreneur of the Year ... in the field of home healthcare, and the innovative work they have done ...
(Date:7/28/2015)... ... July 28, 2015 , ... VAZATA, a ... expanding their cloud presence to support their rapidly growing business. , Headquarted in ... been serving the Dallas/Fort Worth area for almost 50 years. HeartPlace is recognized ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step ... Center located at Gary Avenue and Lies Road in Carol Stream. All are welcome. ... awareness, and provide education and help to support individuals and families affected by a brain ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... a number of publications, including Runner’s World Magazine, is plantar fasciitis . ... constant pain. , Designed by a professional athletic trainer, the Zensah Ankle ...
Breaking Medicine News(10 mins):Health News:Coco Libre Wins 2015 NCW Eco-Excellence Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2
... affect brain function in adults who have few or ... results of the first study to examine cognitive functioning ... funded by the National Heart, Lung, and Blood Institute ... brain function scores and imaging tests in adult patients ...
... lead to future treatments, researchers say , TUESDAY, May ... that are linked to Alzheimer,s disease and could become ... Genetic variants appear to play an important part in ... with the disease increases a person,s risk. It is ...
... out of every ten pregnant women in the United States are ... the May issue of the American Journal of Obstetrics and ... pregnancy, the study shows that higher doses may be needed for ... Denver School of Medicine, lead author of the study said, "We ...
... facts and don,t recognize the symptoms, U.S. survey reveals , TUESDAY, ... women finds only about one in four women aged 25 to ... , This is important because researchers say it takes longer for ... a stroke, and researchers think lack of awareness about symptoms may ...
... ... hierarchically rather than serially, to deliver highly responsive, customer-oriented presentations. , ... London, UK (PRWEB) ... Designer is now available for Microsoft® Office PowerPoint®. This new software enables ...
... 11, 2010 Complex issues in interventional cardiology ... lab will be the focus of the 19th Annual ... DC. The symposium is being held in conjunction with ... of the Cardiovascular Research Foundation. "Changes are occurring ...
Cached Medicine News:Health News:New study suggests sickle cell disease may affect brain function in adults 2Health News:New study suggests sickle cell disease may affect brain function in adults 3Health News:New Alzheimer's Risk Genes Identified 2Health News:New Alzheimer's Risk Genes Identified 3Health News:Many pregnant women not getting enough vitamin D 2Health News:Women Often Miss Signs of Stroke 2Health News:GMARK Launches World's First Web-Like, PowerPoint Navigation Software 2Health News:Nurse/tech symposium at TCT 2010 will address complex issues in the cardiac cath lab 2
... enzymatic cleaner is a fast-acting ... stubborn deposits in as little ... enzymatic cleaner contains an enzyme ... film on soft contact lenses ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Sterile cordless eraser tips, packsize is 10/box....
Medicine Products: